Compare MYGN & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYGN | ZVRA |
|---|---|---|
| Founded | 1991 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.2M | 472.9M |
| IPO Year | 1996 | 2015 |
| Metric | MYGN | ZVRA |
|---|---|---|
| Price | $4.16 | $11.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $7.64 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 983.9K | 739.7K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 1.35 |
| Revenue | ★ $771,400,000.00 | $106,470,000.00 |
| Revenue This Year | $6.86 | $37.27 |
| Revenue Next Year | $5.45 | $53.42 |
| P/E Ratio | ★ N/A | $7.90 |
| Revenue Growth | 2.33 | ★ 350.91 |
| 52 Week Low | $3.76 | $7.16 |
| 52 Week High | $8.59 | $13.16 |
| Indicator | MYGN | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 36.06 | 66.68 |
| Support Level | $3.76 | $8.30 |
| Resistance Level | $5.52 | $12.14 |
| Average True Range (ATR) | 0.29 | 0.44 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 25.32 | 98.88 |
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.